(CDAX, Renewables, ABO GR)



Buy		Value Indicators: DCF:		` '	3.0	Description: Independent power producer operating onshore wind and I	
EUR 4.00	(EUR 4.10)			Balance Sheet Score: Market Liquidity Score:	5.0 1.0	projects in Europe	- V
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2023e
		Market cap:	156.08	Freefloat	72.80 %	Beta:	0.7
Price	EUR 2.08	No. of shares (m):	75.04	Tion Renewables	21.90 %	Price / Book:	1.4 x
Upside	92.3 %	EV:	264.42	Union Investment	5.30 %	Equity Ratio:	34 %
		Freefloat MC:	113.63			Net Fin. Debt / EBITDA:	3.3 x
		Ø Trad. Vol. (30d):	19.75 th			Net Debt / EBITDA:	3.3 x

Conference Feedback: Strong FY23 preliminaries but muted outlook, PT down

2023			
2023	2023e	2022	yoy
44.8	42.7	64.0	-30.0%
30.3	29.9 70.0%	20.6 32.2%	47.0%
	2023 44.8 30.3	2023 2023e 44.8 42.7	2023 2023e 2022 44.8 42.7 64.0 30.3 29.9 20.6

Comment on Figures:

- Figures came in slightly better than we were expecting, hinting at supportive weather effects in Q4/23.
- As expected, the drop in power prices resulted in a yoy-decline in revenue and margin generation.
- With its FY 2023 report, clearvise will change to reporting in accordance with IFRS rather than HGB, which will cause some deviation from our current model owing to the reclassification of cost positions.

Preliminary FY 2023 figures were slightly ahead of our estimates. Higher revenues hint at supportive weather effects in Q4/23, though the sharp decline in power prices resulted in a yoy-decline in sales and margin generation. However, the operating EBITDA does not include the additional income from the disposal of assets in Finland (WRe: EUR 5.4m), which should bolster EBITDA generation and support the cash position. With the FY 2023 report, clearvise will change from reporting in accordance with HGB to IFRS, which will trigger the reclassification of some P&L positions and the revaluation of several balance sheet positions. According to the management presentation at our "Meet-the-Future: Renewables" conference in Frankfurt last week, the equity ratio will increase to 44%, creating additional headroom for new acquisitions.

Portfolio reshuffling results in sales decline: The sale of the Finnish assets in 2023 and divestment of the sole biogas plant in early 2024 will result in a further revenue decline in 2024. However, the released funds will be used to acquire new assets in accordance with the company's investment strategy and allow the company to grow its top line and margin in the next years. In particular, the clearPartners approach, which is used to establish co-development vehicles with local developers, should allow for better capital allocation at attractive returns.

The outlook for 2024 will be published with the final figures on April 30, though we expect a **muted guidance** based on the postponement of grid connections and longer construction times for new builds. We previously expected two larger PV parks to contribute to this year's P&L but have pushed out the COD of the respective parks to late 2024 or early 2025, which affects our 2024 estimates. However, the secured pipeline remains well-filled and we expect the pace of acquisition to pick up in 2025/26, laying a solid basis for upbeat revenue and margin development.

With the release of the FY 2023 report, we will publish a model update to comply with the IFRS reporting.

Changes in E	stimates:					
FY End: 31.12. in EUR m	2023e (old)	+/-	2024e (old)	+ / -	2025e (old)	+/-
Sales	43.81	2.3 %	42.31	-12.2 %	47.96	-3.2 %
EBITDA	37.60	-4.1 %	29.77	-15.7 %	33.79	-4.7 %
EBIT	13.25	-9.1 %	4.34	n.m.	6.39	-18.2 %

FY 2023

Q2

Comment on Changes:

- Later COD of new acquisitions reflect the longer construction times and delays in connecting new builds to the grid.
- However, we will have to update our model in line with the IFRS reporting, which is likely to trigger further changes in our forecast.



Rel. Performance vs CDAX:	
1 month:	0.5 %
6 months:	-12.1 %
Year to date:	-8.6 %
Trailing 12 months:	-20.5 %


FY End: 31.12. in EUR m	CAGR (22-25e)	2019	2020	2021	2022	2023e	2024e	2025e
Sales	-10.2 %	33.08	36.45	32.88	64.03	44.80	37.13	46.40
Change Sales yoy		4.4 %	10.2 %	-9.8 %	94.7 %	-30.0 %	-17.1 %	25.0 %
Gross profit margin		99.2 %	98.9 %	98.9 %	99.6 %	99.3 %	100.0 %	100.0 %
EBITDA	-12.4 %	26.03	27.68	21.84	47.86	36.05	25.10	32.20
Margin		78.7 %	75.9 %	66.4 %	74.7 %	80.5 %	67.6 %	69.4 %
EBIT	-40.9 %	6.78	9.13	2.91	25.28	12.04	-0.34	5.23
Margin		20.5 %	25.1 %	8.8 %	39.5 %	26.9 %	-0.9 %	11.3 %
Net income	-57.4 %	-0.40	2.35	-3.28	11.61	3.79	-3.32	0.90
EPS	-62.5 %	-0.01	0.05	-0.06	0.19	0.05	-0.04	0.01
EPS adj.	-62.5 %	-0.01	0.05	-0.06	0.19	0.05	-0.04	0.01
DPS	-	0.01	0.02	0.00	0.00	0.00	0.00	0.00
Dividend Yield		0.6 %	1.0 %	n.a.	n.a.	n.a.	n.a.	n.a.
FCFPS		0.47	0.54	0.05	0.34	-0.64	0.13	-0.28
FCF / Market cap		27.7 %	26.6 %	2.0 %	14.1 %	-30.8 %	6.1 %	-13.5 %
EV / Sales		6.8 x	6.1 x	8.2 x	4.2 x	6.1 x	7.1 x	6.2 x
EV / EBITDA		8.6 x	8.0 x	12.4 x	5.6 x	7.6 x	10.6 x	8.9 x
EV / EBIT		33.1 x	24.2 x	93.1 x	10.6 x	22.8 x	n.a.	54.7 x
P/E		n.a.	40.4 x	n.a.	12.6 x	41.6 x	n.a.	208.0 x
FCF Potential Yield		11.0 %	11.8 %	7.5 %	15.2 %	12.2 %	9.9 %	11.1 %
Net Debt		141.84	121.87	139.35	123.53	118.00	108.34	129.45
ROE		-1.1 %	6.2 %	-6.9 %	14.4 %	3.5 %	-3.1 %	0.8 %
ROCE (NOPAT)		n.a.	3.1 %	2.9 %	7.3 %	3.2 %	n.a.	1.7 %
Guidance:	2023: sales of	EUR 42-45n	n; adj. EBITD	A EUR 26-2	9m			

30.04.24

12.09.24

Company events:






Company Background

- · Clearvise is a German IPP, focusing on the operation of European onshore wind and PV parks.
- The acquisition strategy of clearvise is based on three pillars (I) clearValue (II) clearSwitch and (III) clearPartners. The management has expanded the portfolio by more than 140% in only 3 years.
- All three route-to-markets are already proven with at least one successful acquisition. Primary object was the addition of PV projects to diversify the portfolio and optimize output.
- Within the clearScale growth strategy, clearvise targets to reach an portfolio size of 1GW (750MW operating & 250MW pipeline).
- To leverage the company's development know-how and use the opportunities of new technology's, the management can allocate up to 20% of the capital into development projects, cooperation or new technologies.

Competitive Quality

- A highly-experienced team of industry experts, capable of operating and optimizing the current portfolio, has developed a lean platform for the integration of further acquisitions.
- Clearvise has introduced a three-pronged market access strategy; clearVALUE, clearPARTNERS and clearSWITCH; to gain a competitive edge and establish a niche market position.
- The market access strategies target the current market as well as the market transition and should allow for profitable growth.
- The technical expertise of the management team and experience with the operation of the former ABO Invest portfolio allows for optimization measures, which will result in higher output.
- By expanding the investment focus of PV projects, the top-line and margins should stabilize further, providing highly visible and predictable cash-flows.





Figures in EU	ID m			d forecast p		2020-	0007-	0000-	2020-	Transition	•	2022-	0000-	0004-	2025-	0000-	0007-	2020-	0000-	2046
	JK M		2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e	2037e	2038e	2039e	2040
Sales Sales change	•		44.8 -30.0 %	37.1 -17.1 %	46.4 25.0 %	47.0 1.3 %	44.2 -6.0 %	44.5 0.8 %	45.2 1.6 %	46.1 2.0 %	46.1 -0.1 %	47.0 2.1 %	47.5 0.9 %	48.2 1.5 %	49.1 1.9 %	50.4 2.7 %	51.8 2.8 %	52.3 1.1 %	53.0 1.2 %	50. -4.5 9
EBIT			12.0	-0.3	5.2	5.6	3.7	3.9	4.4	5.1	5.6	6.3	6.6	7.1	7.7	30.6	35.8	36.2	36.6	35.
EBIT-margin Tax rate (EB	7)		26.9 %	-0.9 % 30.0 %	11.3 % 30.0 %	12.0 % 29.0 %	8.3 % 28.0 %	8.8 % 26.0 %	9.7 % 26.0 %	11.1 % 26.0 %	12.2 % 26.0 %	13.4 % 26.0 %	13.9 % 26.0 %	14.8 % 26.0 %	15.8 % 26.0 %	60.8 % 26.0 %	69.1 % 26.0 %	69.1 % 26.0 %	69.1 % 26.0 %	69.1 9 26.0 9
NOPAT	')		30.0 % 8.4	-0.2	30.0 %	4.0	26.0 %	2.0 %	3.3	3.8	4.2	4.7	4.9	5.3	5.7	20.0 %	26.5	26.8	20.0 %	25.
Depreciation			24.0	25.4	27.0	27.0	27.0	27.0	27.0	26.9	26.3	26.3	26.3	26.3	26.3	4.3	0.1	0.1	0.1	0.
in % of Sales Change in pro			53.6 %	68.5 % 0.0	58.1 % 0.0	57.4 % 0.0	61.1 % 0.0	60.6 % 0.0	59.6 % 0.0	58.3 % 0.0	57.2 % 0.0	56.0 % 0.0	55.5 % 0.0	54.6 % 0.0	53.6 % 0.0	8.6 % 0.0	0.3 % 0.0	0.3 % 0.0	0.2 % 0.0	0.3 % 0.
Change in liq			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.
- Working Ca - Capex			2.0	-0.7 13.3	0.8 48.2	0.0	-0.3 0.0	0.0 0.0	0.1 0.0	0.1 0.0	0.0 0.0	0.1 0.0	0.0	0.1 0.0	0.1 0.0	0.1 0.0	0.1 0.0	0.0 0.0	0.1 0.0	-0.: 0.
- Capex Capex in % o	f Sales		67.9 151.6 %	35.8 %	103.8 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Other			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Free Cash Fl	ow (WACC-	model)	-37.5	12.6	-18.4	30.9	29.9	29.8	30.2	30.6	30.5	30.9	31.2	31.5	32.0	26.9	26.5	26.9	27.2	26.2
PV of FCF	(117100		-38.3	12.3	-17.2	27.8	25.7	24.6	23.9	23.2	22.2	21.5	20.8	20.2	19.6	15.8	14.9	14.5	14.1	13.0
share of PVs		Ì		-11.4 %						111.	4 %									
																			Т	erm. Value
2041e	2042e	2043e	2044e	2045e	2046e	2047e	2048e	2049e	2050e	2051e	2052e	2053e	2054e	2055e	2056e	2057e	2058e	2059e	2060e	
51.1	51.9	51.6	44.5	43.6	31.8	32.1	32.3	32.6	33.3	33.9	34.6	32.2	32.8	33.4	32.3	22.3	22.8	9.5	9.7	
1.0 % 35.3	1.6 % 35.9	-0.6 % 35.7	-13.7 % 30.8	-2.0 % 30.1	-27.1 % 21.9	1.0 % 22.2	0.6 % 22.4	0.9 % 22.6	2.1 % 23.1	1.9 % 23.5	1.9 % 24.0	-7.0 % 22.3	1.9 % 22.7	1.9 % 23.2	-3.3 % 22.4	-30.8 % 15.5	1.9 % 15.8	-58.2 % 6.6	1.9 % 6.7	0.0 %
69.1 %	69.1 %	69.1 %	69.1 %	69.1 %	69.0 %	69.0 %	69.4 %	69.4 %	69.4 %	69.4 %	69.4 %	69.4 %	69.4 %	69.4 %	69.4 %	69.4 %	69.4 %	69.4 %	69.4 %	
26.0 %	26.0 %	26.0 %	26.0 %	26.0 %	26.0 %	26.0 %	26.0 %	26.0 %	26.0 %	26.0 %	26.0 %	26.0 %	26.0 %	26.0 %	26.0 %	26.0 %	26.0 %	26.0 %	26.0 %	
26.1	26.6	26.4	22.8	22.3	16.2	16.4	16.6	16.7	17.1	17.4	17.7	16.5	16.8	17.1	16.6	11.5	11.7	4.9	5.0	
0.1 0.3 %	0.1 0.2 %	0.1 0.2 %	0.1 0.3 %	0.1 0.3 %	0.1 <i>0.4</i> %	0.1 <i>0.4</i> %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	
0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
0.0	0.1	0.0	-0.6	-0.1	-1.1	0.0	0.0	0.0	0.1	0.1	0.1	-0.2	0.1	0.1	-0.1	-0.9	0.0	-1.2	-0.9	
0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	
0.0 26.2	0.0 26.6	0.0 26.6	0.0 23.5	0.0 22.5	0.0 17.4	0.0 16.5	0.0 16.6	0.0 16.7	0.0 17.0	0.0 17.4	0.0 17.7	0.0 16.7	0.0 16.8	0.0 17.1	0.0 16.7	0.0 12.4	0.0 11.6	0.0 6.1	0.0 5.8	
12.5	12.1	11.6	9.8	9.0	6.7	6.1	5.9	5.7	5.5	5.4	5.3	4.8	4.6	4.5	4.2	3.0	2.7	1.3	1.2	0.0 %
Madal was											Valuation	- ()								
Model par						Dawin - t'	n of D-4				Valuation		1 2000 -		200.5					
Derivation	of WACC	:					n of Beta:				Terminal		i ∠060e		380.5 0.0					
Debt ratio				45.0 %			Strength		0.70		Financial				201.2					
Cost of del Market reti				2.5 % 8.3 %		Liquidity Cyclicalit	v		0.60 0.60		Pension I Hybrid ca				0.0					
Risk free ra				2.8 %		Transpar			0.70		Minority in				0.0					
Risk premi				5.5 %		Others			0.70			al. of inves	tments		0.0					
Cost of eq	uity			6.4 %							Liquidity				125.3			shares (m)	· ·	75.4
WACC				4.34 %		Beta			0.66		Equity V	alue			304.6		Value p	oer share		4.04

			-
Sensitivity Value	per share	(EUR)	

	т	erminal Gro	owth						D	elta EBIT-r	nargin					
Beta	(WACC)	-0.75 %	-0.50 %	-0.25 %	0.00 %	0.25 %	0.50 %	0.75 %		-1.50 pp	-1.00 pp	-0.50 pp	0.0	0.50 pp	1.00 pp	1.50 pp
0.99	(5.3 %)	3.40	3.40	3.40	3.40	3.40	3.40	3.40		3.29	3.33	3.36	3.40	3.44	3.48	3.51
0.83	(4.8 %)	3.71	3.71	3.71	3.71	3.71	3.71	3.71		3.59	3.63	3.67	3.71	3.75	3.79	3.82
0.74	(4.6 %)	3.87	3.87	3.87	3.87	3.87	3.87	3.87		3.75	3.79	3.83	3.87	3.91	3.95	3.99
0.66	(4.3 %)	4.04	4.04	4.04	4.04	4.04	4.04	4.04		3.92	3.96	4.00	4.04	4.08	4.12	4.17
0.58	(4.1 %)	4.22	4.22	4.22	4.22	4.22	4.22	4.22		4.09	4.14	4.18	4.22	4.26	4.31	4.35
0.49	(3.8 %)	4.41	4.41	4.41	4.41	4.41	4.41	4.41		4.28	4.32	4.37	4.41	4.45	4.50	4.54
0.33	(3.3 %)	4.81	4.81	4.81	4.81	4.81	4.81	4.81		4.68	4.72	4.77	4.81	4.86	4.91	4.95

- Our Warburg IPP-DCF approach is a modified valuation approach for the valuation of renewable energy assets.
- Since we can calculate top-line and margin generation of each park over the useful live, we extend our DCF-approach.
- We do not apply a terminal value to our valuation, reflecting the limited life of renewable energy assets.
- For our calculation, we assume a useful life of 30 years for onshore wind and 35 years for PV.
- We only include the current portfolio size of clearvise in our Warburg IPP-DCF.

Clearvise



Valuation							
	2019	2020	2021	2022	2023e	2024e	2025e
Price / Book	2.2 x	2.6 x	2.3 x	1.4 x	1.4 x	1.5 x	1.5 x
Book value per share ex intangibles	0.62	0.66	0.88	1.33	1.39	1.35	1.37
EV / Sales	6.8 x	6.1 x	8.2 x	4.2 x	6.1 x	7.1 x	6.2 x
EV / EBITDA	8.6 x	8.0 x	12.4 x	5.6 x	7.6 x	10.6 x	8.9 x
EV / EBIT	33.1 x	24.2 x	93.1 x	10.6 x	22.8 x	n.a.	54.7 x
EV / EBIT adj.*	33.1 x	24.2 x	93.1 x	10.6 x	22.8 x	n.a.	54.7 x
P / FCF	3.6 x	3.8 x	49.4 x	7.1 x	n.a.	16.5 x	n.a.
P/E	n.a.	40.4 x	n.a.	12.6 x	41.6 x	n.a.	208.0 x
P / E adj.*	n.a.	40.4 x	n.a.	12.6 x	41.6 x	n.a.	208.0 x
Dividend Yield	0.6 %	1.0 %	n.a.	n.a.	n.a.	n.a.	n.a.
FCF Potential Yield (on market EV)	11.0 %	11.8 %	7.5 %	15.2 %	12.2 %	9.9 %	11.1 %
*Adjustments made for: -							


Company Specific Items							
	2019	2020	2021	2022	2023e	2024e	2025e
Output in GWh	385	426	367	493	509	467	587



Consolidated profit & loss							
In EUR m	2019	2020	2021	2022	2023e	2024e	2025
Sales	33.08	36.45	32.88	64.03	44.80	37.13	46.40
Change Sales yoy	4.4 %	10.2 %	-9.8 %	94.7 %	-30.0 %	-17.1 %	25.0 %
Increase / decrease in inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Own work capitalised	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Sales	33.08	36.45	32.88	64.03	44.80	37.13	46.40
Material expenses	0.28	0.40	0.35	0.28	0.33	0.00	0.00
Gross profit	32.81	36.05	32.53	63.75	44.47	37.13	46.40
Gross profit margin	99.2 %	98.9 %	98.9 %	99.6 %	99.3 %	100.0 %	100.0 %
Personnel expenses	0.22	0.30	0.66	1.23	1.30	1.50	1.87
Other operating income	1.57	0.94	0.22	0.49	5.84	0.55	0.69
Other operating expenses	8.12	9.00	10.25	15.15	12.96	11.09	13.02
Unfrequent items	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	26.03	27.68	21.84	47.86	36.05	25.10	32.20
Margin	78.7 %	75.9 %	66.4 %	74.7 %	80.5 %	67.6 %	69.4 %
Depreciation of fixed assets	19.25	18.55	18.93	21.95	23.38	24.81	26.34
EBITA	6.78	9.13	2.91	25.91	12.67	0.29	5.86
Amortisation of intangible assets	0.00	0.00	0.00	0.63	0.63	0.63	0.63
Goodwill amortisation	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT	6.78	9.13	2.91	25.28	12.04	-0.34	5.23
Margin	20.5 %	25.1 %	8.8 %	39.5 %	26.9 %	-0.9 %	11.3 %
EBIT adj.	6.78	9.13	2.91	25.28	12.04	-0.34	5.23
Interest income	0.00	0.00	0.02	0.00	0.00	0.00	0.00
Interest expenses	5.79	5.13	4.72	6.60	5.80	4.15	4.02
Other financial income (loss)	0.02	0.02	0.02	0.00	0.00	0.00	0.00
EBT	0.98	3.98	-1.81	18.68	6.24	-4.49	1.21
Margin	3.0 %	10.9 %	-5.5 %	29.2 %	13.9 %	-12.1 %	2.6 %
Total taxes	1.38	1.63	1.47	7.07	2.45	-1.17	0.31
Net income from continuing operations	-0.40	2.35	-3.28	11.61	3.79	-3.32	0.90
Income from discontinued operations (net of tax)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net income before minorities	-0.40	2.35	-3.28	11.61	3.79	-3.32	0.90
Minority interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net income	-0.40	2.35	-3.28	11.61	3.79	-3.32	0.90
Margin	-1.2 %	6.4 %	-10.0 %	18.1 %	8.5 %	-8.9 %	1.9 %
Number of shares, average	49.00	49.00	53.78	60.04	75.36	75.36	75.36
EPS	-0.01	0.05	-0.06	0.19	0.05	-0.04	0.01
EPS adj.	-0.01	0.05	-0.06	0.19	0.05	-0.04	0.01
*Adjustments made for:							

Guidance: 2023: sales of EUR 42-45m; adj. EBITDA EUR 26-29m

Financial Ratios							
	2019	2020	2021	2022	2023e	2024e	2025e
Total Operating Costs / Sales	21.3 %	24.1 %	33.6 %	25.3 %	19.5 %	32.4 %	30.6 %
Operating Leverage	1.0 x	3.4 x	7.0 x	8.1 x	1.7 x	n.a.	n.a.
EBITDA / Interest expenses	4.5 x	5.4 x	4.6 x	7.2 x	6.2 x	6.0 x	8.0 x
Tax rate (EBT)	141.0 %	41.0 %	-80.9 %	37.9 %	39.2 %	26.0 %	26.0 %
Dividend Payout Ratio	n.m.	41.8 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Sales per Employee	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.




Source: Warburg Research Source: Warburg Research

Source: Warburg Research



Consolidated balance sheet							
In EUR m	2019	2020	2021	2022	2023e	2024e	2025
Assets							
Goodwill and other intangible assets	6.83	6.20	5.57	4.94	4.31	3.68	3.05
thereof other intangible assets	0.00	0.00	0.00	0.00	-0.63	-1.26	-1.89
thereof Goodwill	6.83	6.20	5.57	4.94	4.94	4.94	4.94
Property, plant and equipment	176.04	157.78	191.33	261.84	258.74	247.24	269.08
Financial assets	0.23	0.21	0.19	0.17	0.17	0.17	0.17
Other long-term assets	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed assets	183.10	164.19	197.09	266.95	263.22	251.09	272.30
Inventories	0.16	0.20	0.29	0.23	0.20	0.20	0.20
Accounts receivable	4.48	5.31	5.85	6.93	4.90	4.00	5.00
Liquid assets	14.68	17.32	23.20	77.67	49.75	39.66	28.22
Other short-term assets	0.65	0.89	4.49	6.50	6.50	6.50	6.50
Current assets	19.97	23.73	33.83	91.33	61.34	50.36	39.91
Total Assets	203.10	187.90	230.90	358.30	324.60	301.40	312.20
Liabilities and shareholders' equity							
Subscribed capital	49.00	49.00	57.40	75.36	75.36	75.36	75.36
Capital reserve	13.27	13.27	25.59	44.75	44.75	44.75	44.75
Retained earnings	0.46	0.99	0.99	0.99	4.78	1.46	2.35
Other equity components	-25.36	-24.50	-27.78	-16.16	-16.06	-16.06	-15.96
Shareholders' equity	37.37	38.76	56.20	104.94	108.83	105.51	106.50
Minority interest	4.90	4.89	4.88	0.00	0.00	0.00	0.00
Total equity	42.27	43.64	61.08	104.94	108.83	105.51	106.50
Provisions	2.38	2.69	3.02	9.78	9.78	9.78	9.78
thereof provisions for pensions and similar obligations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial liabilities (total)	156.51	139.19	162.55	201.19	167.75	148.00	157.67
Short-term financial liabilities	17.53	18.35	0.00	26.61	23.67	23.67	23.67
Accounts payable	1.00	0.91	1.42	5.10	1.00	0.80	1.00
Other liabilities	0.91	1.48	2.88	37.30	37.30	37.30	37.30
Liabilities	160.80	144.27	169.86	253.37	215.82	195.87	205.74
Total liabilities and shareholders' equity	203.10	187.90	230.90	358.30	324.60	301.40	312.20


Financial Ratios							
	2019	2020	2021	2022	2023e	2024e	2025e
Efficiency of Capital Employment							
Operating Assets Turnover	0.2 x	0.1 x	0.2 x				
Capital Employed Turnover	0.2 x	0.2 x	0.2 x	0.3 x	0.2 x	0.2 x	0.2 x
ROA	-0.2 %	1.4 %	-1.7 %	4.3 %	1.4 %	-1.3 %	0.3 %
Return on Capital							
ROCE (NOPAT)	n.a.	3.1 %	2.9 %	7.3 %	3.2 %	n.a.	1.7 %
ROE	-1.1 %	6.2 %	-6.9 %	14.4 %	3.5 %	-3.1 %	0.8 %
Adj. ROE	-1.1 %	6.2 %	-6.9 %	14.4 %	3.5 %	-3.1 %	0.8 %
Balance sheet quality							
Net Debt	141.84	121.87	139.35	123.53	118.00	108.34	129.45
Net Financial Debt	141.84	121.87	139.35	123.53	118.00	108.34	129.45
Net Gearing	335.5 %	279.2 %	228.2 %	117.7 %	108.4 %	102.7 %	121.6 %
Net Fin. Debt / EBITDA	544.9 %	440.3 %	638.2 %	258.1 %	327.3 %	431.7 %	402.1 %
Book Value / Share	0.8	0.8	1.0	1.4	1.4	1.4	1.4
Book value per share ex intangibles	0.6	0.7	0.9	1.3	1.4	1.4	1.4





Consolidated cash flow statement							
In EUR m	2019	2020	2021	2022	2023e	2024e	2025
Net income	-0.40	2.37	-3.28	11.62	3.79	-3.32	0.90
Depreciation of fixed assets	19.25	18.55	18.93	22.59	23.38	24.81	26.34
Amortisation of goodwill	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Amortisation of intangible assets	0.00	0.00	0.00	0.63	0.63	0.63	0.63
Increase/decrease in long-term provisions	0.17	0.38	0.00	1.35	0.00	0.00	0.00
Other non-cash income and expenses	4.70	6.27	5.25	11.92	-6.10	0.00	0.00
Cash Flow before NWC change	23.72	27.56	20.90	48.10	21.70	22.11	27.86
Increase / decrease in inventory	0.00	-0.04	-1.19	4.98	0.03	0.00	0.00
Increase / decrease in accounts receivable	0.16	-0.83	-1.23	0.00	2.03	0.90	-1.00
Increase / decrease in accounts payable	-0.96	-0.08	0.00	-4.22	-4.10	-0.20	0.20
Increase / decrease in other working capital positions	0.00	0.00	0.00	-0.70	0.00	0.00	0.00
Increase / decrease in working capital (total)	-0.80	-0.96	-2.42	0.06	-2.04	0.70	-0.80
Net cash provided by operating activities [1]	22.92	26.61	18.48	48.17	19.66	22.81	27.06
Investments in intangible assets	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Investments in property, plant and equipment	0.00	-0.26	-15.82	-27.84	-67.93	-13.30	-48.18
Payments for acquisitions	0.00	0.00	-14.54	-28.05	0.00	0.00	0.00
Financial investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income from asset disposals	1.07	0.36	0.00	0.00	0.00	0.15	0.00
Net cash provided by investing activities [2]	0.97	0.10	-30.35	-55.88	-14.14	-13.15	-48.18
Change in financial liabilities	-17.99	-17.34	1.69	30.32	-33.44	-19.75	9.67
Dividends paid	-0.49	-0.98	0.00	0.00	0.00	0.00	0.00
Purchase of own shares	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital measures	0.00	0.00	20.72	37.12	0.00	0.00	0.00
Other	-5.77	-5.05	-4.68	-5.32	0.00	0.00	0.00
Net cash provided by financing activities [3]	-24.25	-23.37	17.73	62.12	-33.44	-19.75	9.67
Change in liquid funds [1]+[2]+[3]	-0.35	3.34	5.86	54.40	-27.92	-10.08	-11.45
Effects of exchange-rate changes on cash	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash and cash equivalent at end of period	14.19	18.02	23.18	77.60	49.75	39.66	28.22

Financial Ratios							
	2019	2020	2021	2022	2023e	2024e	2025e
Cash Flow							
FCF	22.82	26.34	2.66	20.33	-48.26	9.51	-21.12
Free Cash Flow / Sales	69.0 %	72.3 %	8.1 %	31.7 %	-107.7 %	25.6 %	-45.5 %
Free Cash Flow Potential	24.65	26.05	20.37	40.79	33.60	26.26	31.88
Free Cash Flow / Net Profit	-5690.9 %	1123.0 %	-81.0 %	175.1 %	-1272.9 %	-286.5 %	-2358.7 %
Interest Received / Avg. Cash	0.0 %	0.0 %	0.1 %	0.0 %	0.0 %	0.0 %	0.0 %
Interest Paid / Avg. Debt	3.5 %	3.5 %	3.1 %	3.6 %	3.1 %	2.6 %	2.6 %
Management of Funds							
Investment ratio	0.0 %	0.7 %	48.1 %	43.5 %	151.6 %	35.8 %	103.8 %
Maint. Capex / Sales	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Capex / Dep	0.0 %	1.4 %	83.6 %	123.3 %	282.9 %	52.3 %	178.7 %
Avg. Working Capital / Sales	10.4 %	11.3 %	14.2 %	5.3 %	6.9 %	10.1 %	8.2 %
Trade Debtors / Trade Creditors	449.1 %	582.1 %	413.1 %	135.9 %	490.0 %	500.0 %	500.0 %
Inventory Turnover	1.7 x	1.9 x	1.2 x	1.2 x	1.7 x	0.0 x	0.0 x
Receivables collection period (days)	49	53	65	40	40	39	39
Payables payment period (days)	1,321	837	1,460	6,582	1,103	n.a.	n.a.
Cash conversion cycle (Days)	-1,055	-597	-1,094	-6,243	-842	n.a.	n.a.





LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The Warburg ESG Risk Score is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.



Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
- 3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
- 4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
- 5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or**investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

This report has been made accessible to the company analysed.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Clearvise	3, 5	https://www.mmwarburg.com/disclaimer/disclaimer en/DE000A1EWXA4.htm



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

<u>"_"</u>	Rating suspended:	The available information currently does not permit an evaluation of the company.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.

Rating	Number of stocks	% of Universe
Buy	147	71
Hold	46	22
Sell	8	4
Rating suspended	7	3
Total	208	100

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	46	81
Hold	8	14
Sell	0	0
Rating suspended	3	5
Total	57	100

PRICE AND RATING HISTORY CLEARVISE AS OF 25.04.2024



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



EQUITIES			
Matthias Rode	+49 40 3282-2678		
Head of Equities	mrode@mmwarburg.com		
RESEARCH			
Michael Heider Head of Research	+49 40 309537-280 mheider@warburg-research.com	Thilo Kleibauer Retail, Consumer Goods	+49 40 309537-257 tkleibauer@warburg-research.com
Henner Rüschmeier Head of Research	+49 40 309537-270 hrueschmeier@warburg-research.com	Hannes Müller Software, IT	+49 40 309537-255 hmueller@warburg-research.com
Stefan Augustin	+49 40 309537-168	Andreas Pläsier	+49 40 309537-246
Cap. Goods, Engineering	saugustin@warburg-research.com	Banks, Financial Services	aplaesier@warburg-research.com
Jan Bauer	+49 40 309537-155	Malte Schaumann	+49 40 309537-170
Renewables	jbauer@warburg-research.com	Technology	mschaumann@warburg-research.com
Sander Brockow Industrials	+49 40 309537-248 sbrockow@warburg-research.com	Oliver Schwarz Chemicals, Agriculture	+49 40 309537-250 oschwarz@warburg-research.com
Christian Cohrs	+49 40 309537-175	Simon Stippig	+49 40 309537-265
Industrials & Transportation	ccohrs@warburg-research.com	Real Estate, Telco	sstippig@warburg-research.com
Dr. Christian Ehmann BioTech, Life Science	+49 40 309537-167	Marc-René Tonn	+49 40 309537-259
Felix Ellmann	cehmann@warburg-research.com +49 40 309537-120	Automobiles, Car Suppliers Robert-Jan van der Horst	mtonn@warburg-research.com +49 40 309537-290
Software, IT	fellmann@warburg-research.com	Technology	rvanderhorst@warburg-research.com
Jörg Philipp Frey	+49 40 309537-258	Andreas Wolf	+49 40 309537-140
Retail, Consumer Goods	jfrey@warburg-research.com	Software, IT	awolf@warburg-research.com
Marius Fuhrberg Financial Services	+49 40 309537-185 mfuhrberg@warburg-research.com		
Fabio Hölscher	+49 40 309537-240		
Automobiles, Car Suppliers	fhoelscher@warburg-research.com		
Philipp Kaiser	+49 40 309537-260		
Real Estate, Construction	pkaiser@warburg-research.com		
INSTITUTIONAL EQU		Dudalf Alayandan Miahaalia	. 40, 40, 2000, 2040
Klaus Schilling Head of Equity Sales, Germany	+49 69 5050-7400 kschilling@mmwarburg.com	Rudolf Alexander Michaelis Germany	+49 40 3282-2649 rmichaelis@mmwarburg.com
Tim Beckmann	+49 40 3282-2665	Roman Alexander Niklas	+49 69 5050-7412
United Kingdom	tbeckmann@mmwarburg.com	Switzerland	rniklas@mmwarburg.com
Lea Bogdanova	+49 69 5050-7411		
United Kingdom, Ireland Jens Buchmüller	lbogdanova@mmwarburg.com +49 69 5050-7415	Antonia Möller	+49 69 5050-7417
Scandinavia, Austria	jbuchmueller@mmwarburg.com	Roadshow/Marketing	amoeller@mmwarburg.com
Matthias Fritsch	+49 40 3282-2696	Charlotte Wernicke	+49 40 3282-2669
United Kingdom	mfritsch@mmwarburg.com	Roadshow/Marketing	cwernicke@mmwarburg.com
Maximilian Martin	+49 69 5050-7413	Juliane Niemann	+49 40 3282-2694
Austria, Poland	mmartin@mmwarburg.com	Roadshow/Marketing	jniemann@mmwarburg.com
SALES TRADING	40.40.0000.0004	DESIGNATED SPONSOR	
Oliver Merckel Head of Sales Trading	+49 40 3282-2634 omerckel@mmwarburg.com	Marcel Magiera Designated Sponsoring	+49 40 3282-2662 mmagiera@mmwarburg.com
Rico Müller	+49 40 3282-2685	Sebastian Schulz	+49 40 3282-2631
Sales Trading	rmueller@mmwarburg.com	Designated Sponsoring	sschulz@mmwarburg.com
Bastian Quast	+49 40 3282-2701	Jörg Treptow	+49 40 3282-2658
Sales Trading	bquast@mmwarburg.com	Designated Sponsoring	jtreptow@mmwarburg.com
MACRO RESEARCH			
Carsten Klude Macro Research	+49 40 3282-2572 cklude@mmwarburg.com	Dr. Christian Jasperneite	+49 40 3282-2439
		Investment Strategy	cjasperneite@mmwarburg.com
Our research can be f		1000	
Warburg Research	research.mmwarburg.com/en/index.html	LSEG	www.lseg.com
Bloomberg	RESP MMWA GO	Capital IQ	www.capitaliq.com
FactSet	www.factset.com		
For access please conta	act:		
Andrea Schaper	+49 40 3282-2632	Kerstin Muthig	+49 40 3282-2703
Sales Assistance	aschaper@mmwarburg.com	Sales Assistance	kmuthig@mmwarburg.com